Biophytis SA

09/03/2025 | Press release | Distributed by Public on 09/02/2025 23:08

Biophytis obtains EMA authorization to launch its Phase 2 clinical trial in obesity

03 Sep 2025 07:00 CEST

Subscribe

Issuer

BIOPHYTIS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1355837_Approval_EMA_Biophytis_Phase_2_OBA_Sept_2025_VENG.pdf

Source

Biophytis

Provider

Les Echos

Company Name

BIOPHYTIS

ISIN

FR001400OLP5

Symbol

ALBPS

Market

Euronext Growth

Biophytis SA published this content on September 03, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 03, 2025 at 05:08 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]